Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications.
about
Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia.Diagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary RoundtableJakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera.Advances and challenges in the management of essential thrombocythemia.Hydroxyurea therapy for sickle cell anemia.
P2860
Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications.
description
1994 nî lūn-bûn
@nan
1994 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի մարտին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Acute leukaemia after hydroxyu ...... with therapeutic implications.
@ast
Acute leukaemia after hydroxyu ...... with therapeutic implications.
@en
type
label
Acute leukaemia after hydroxyu ...... with therapeutic implications.
@ast
Acute leukaemia after hydroxyu ...... with therapeutic implications.
@en
prefLabel
Acute leukaemia after hydroxyu ...... with therapeutic implications.
@ast
Acute leukaemia after hydroxyu ...... with therapeutic implications.
@en
P2093
P1476
Acute leukaemia after hydroxyu ...... with therapeutic implications
@en
P2093
P304
P356
10.1111/J.1600-0609.1994.TB01303.X
P577
1994-03-01T00:00:00Z